Prellis Biologics is a Berkeley, California biotech that 3D-prints human lymph node organoids to grow real human antibodies in a dish. Its EXIS platform uses holographic two-photon laser bioprinting plus AI to recreate the human immune response in vitro, discovering fully human antibody therapeutics faster and cheaper than animal-based methods, including against difficult targets like GPCRs where mouse models fail.
Dimension Bio (formerly Dimension Inx) is a Chicago-based regenerative therapeutics company that turns living cells into implantable, tissue-like therapies. Its BioNidum platform fuses materials science, 3D printing, and digital manufacturing to build three-dimensional microenvironments that help transplanted cells survive, vascularize, and function in the body. A Northwestern University spinout, the company already brought the first FDA-cleared 3D-printed regenerative bone graft (CMFlex) to patients and is now aiming its lead program at acute liver failure - building an engineered, mini-liver-like therapy to stabilize patients and give their own organs a chance to recover.